My speculation is that the MOA and disease between the IV and the nasal spray is so different that the two would not really be comparable.
The IV trial was high dosage in the blood stream against entrenched moderate to severe COVID.
The nasal spray/inhaler, I assume, is to for a prophylactic barrier in the nasal passageways that destroys viral particles before they attach.
There was previously some successful data using aerosolized defensins against MERS about a decade ago. However, with the volume of viral shedding, particularly in the Delta and Omicron variants, I'm not sure such a strategy would be all that effective against modern COVID strains.
Hopefully time will tell.
As you say though, it would be nice if they could spell things out very clearly for us especially when the company constantly changes course.